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•	Because	 of	 high	 cost	 and	 lack	 of	 evidence	 of	 efficacy	 or	
safety,	 antipsychotic	 polytherapy,	 the	 prescribing	 of	 2	 or	more	
antipsychotics,	 is	 discouraged	 in	 treatment	 guidelines	 except	
under	 limited	 circumstances	 (e.g.	 cross–titration	 when	 switch-
ing	medications	 or	 failure/ineligibility	 for	 clozapine	 treatment).	
Nonetheless,	 antipsychotic	 polytherapy	 is	 highly	 prevalent	 in	
psychiatric	inpatient	units,	with	rates	of	30%-40%	in	studies	of	
acutely	hospitalized	patients.
•	The	 Joint	 Commission’s	 first	 set	 of	 hospital-based	 inpatient	
psychiatric	 services	 (HBIPS)	 core	measures	 (2008)	 included	 (a)	
decreasing	 antipsychotic	 polytherapy	 at	 time	 of	 discharge	 and	
(b)	 documentation	 of	 appropriate	 justification	 for	 antipsychotic	
polytherapy,	with	appropriate	justification	defined	as	a	history	of	
3	or	more	failed	antipsychotic	monotherapy	trials,	cross-titrating	
antipsychotic	medications	with	the	ultimate	goal	of	antipsychotic	
monotherapy,	or	clozapine	augmentation.	
•	The	results	of	algorithms	for	decreasing	psychotropic	polytherapy	
and	 antipsychotic	 polytherapy	 have	 been	mixed.	 Thompson	 et	
al.	(2007)	found	that	the	likelihood	of	receiving	polytherapy	was	
decreased	after	implementing	a	system	of	chart	reminders,	educa-
tion,	 and	cognitive	behavioral	 techniques	but	 reported	 that	 the	
improvements	were	 of	 limited	 benefit	 given	 the	 labor-intensive	
nature	of	the	intervention.
What is already known about this subject
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ABSTRACT
BACKGROUND: Although antipsychotic polytherapy is considered appropri-
ate in limited circumstances (e.g., during a brief “cross-titration” period 
when switching medications), its increasing prevalence indicates use 
beyond this limited scope. Despite absence of support in the medical 
literature and higher costs, antipsychotic polytherapy is common in the 
treatment of schizophrenia and related disorders. The highest utilization 
of antipsychotic polytherapy occurs on psychiatric inpatient units, and 
in 2008, the Joint Commission released the first set of 7 hospital-based 
inpatient psychiatric services (HBIPS) core measures, 2 of which assess 
antipsychotic polytherapy at time of discharge.
OBJECTIVE: To describe the effect on antipsychotic polytherapy at time of 
discharge of a 2-part quality improvement program composed of educa-
tional seminars and prescriber-specific feedback provided to 11 psychia-
trists in 4 acute inpatient psychiatric units in 2 hospitals.
METHODS: In a regional academic health care system, we determined 
the prevalence of antipsychotic monotherapy and polytherapy at time of 
discharge for all patients discharged on standing antipsychotic medica-
tions during 3 periods: (a) a 3-month baseline period (August 2006 through 
October 2006); (b) in July 2007, after delivery of 4 educational luncheon 
seminars to 11 psychiatrists from November 2006 through June 2007; and 
(c) in June 2008, following the provision of monthly prescriber-specific 
audit feedback from August 2007 through June 2008. To prepare nurses for 
the change and address possible safety concerns, an educational module 
was delivered to the psychiatric nursing staff at “best practice” day lec-
tures held in the first quarter of 2007. General themes in the educational 
presentations included literature-based reviews of (a) safety and efficacy 
of antipsychotic polytherapy, (b) medical risks of antipsychotic medica-
tions, (c) specific versus nonspecific effects of these medications, and (d) 
effectiveness of first- versus second-generation antipsychotic medications. 
The prescriber-specific audit feedback was provided in paper form and 
masked the identity of the other prescribers. The chief of service reviewed 
audit feedback individually with each psychiatrist on a quarterly basis. The 
primary outcome measure was the percentage of patients prescribed 2 or 
more antipsychotics at discharge. A secondary outcome measure was the 
percentage of patients prescribed 3 or more antipsychotics at discharge. 
Differences in the primary outcome measure, comparing (a) July 2007 
with the baseline period and (b) June 2008 with July 2007, were analyzed 
using Fisher’s Exact tests. The Cochran-Armitage test for trend was used 
to assess the relationship between the primary outcome measure and the 
extent of the intervention, measured as the 3 time periods. For the sec-
ondary outcome measure, the Goodman-Kruskal gamma test for ordered 
categorical data was calculated to examine the association between the  
the proportion of patients receiving 1, 2, or 3 or more antipsychotics at dis-
charge and the 3 time periods.
RESULTS: The percentage of patients prescribed 2 or more antipsychotics 
at discharge declined from 33.9% at baseline (132 of 389 patients), to 
21.8% after delivery of the educational modules (44 of 202 patients, 
P = 0.002), and to 12.2% after audit feedback (18 of 147 patients, P = 0.023; 
Cochran-Armitage test for trend P < 0.001). When antipsychotic use was 
classified as 1, 2, or 3 or more antipsychotic medications, more extensive 
intervention was associated with decreased  combination use (Goodman-
Kruskal gamma = 0.39, P < 0.001). In the baseline period, 5.9% of patients 
were prescribed 3 or more antipsychotics at discharge. Following comple-
tion of the educational and audit components, respectively, the proportion 
of patients prescribed 3 or more antipsychotics declined to 2.5% and then 
to 0.0%.
CONCLUSION: Educational modules presented to psychiatrists and nurses 
in group settings were associated with a decrease in the rate of prescrib-
ing 2 or more antipsychotics at discharge from acute psychiatric inpatient 
units. Addition of monthly audit feedback provided to psychiatrists was 
associated with further decreases.
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prescribed	in	up	to	40%	of	psychiatric	inpatients.19-21	However,	
no	antipsychotic	is	approved	for	adjunctive	use	with	other	anti-
psychotic	agents,	and	such	practice	is	discouraged	in	treatment	
guidelines.22-25
Not	all	antipsychotic	polytherapy	is	unjustified.	For	exam-
ple,	 treatment	 guidelines	 suggest	 that	 cross-titration	 of	 anti-
psychotics	is	preferable	to	abrupt	discontinuation	of	a	medica-
tion	when	switching	from	one	drug	to	another.23-25	In	addition,	
treatment	 guidelines	 suggest	 antipsychotic	 polytherapy	 for	
patients	 who	 are	 treatment	 resistant	 and	 have	 failed	 or	 are	
ineligible	for	a	clozapine	trial.23-25	The	guidelines	caution	that	
such	use	 is	not	 evidence-based,	 should	be	monitored	closely,	
and	discontinued	if	ineffective.23-25 
One	 of	 the	 most	 commonly	 cited	 justifications	 for	 anti-
psychotic	 polytherapy	 is	 treatment	 resistance.26,27	 However,	
data	 suggest	 that	 antipsychotic	 polytherapy	 is	 not	 being	
reserved	 for	 treatment-resistant	 populations.	 Lee	 and	Walker	
(2008)	 reported	 that	 in	patients	 continuously	 enrolled	 in	 the	
California	 Medicaid	 program	 for	 at	 least	 3	 months,	 3.7%	 of	
new	 users	 of	 second-generation	 antipsychotics	 received	 anti-
psychotic	polytherapy	as	their	initial	antipsychotic	treatment.28 
Schumacher	 et	 al.	 (2003)	 found	 that	79	of	85	patients	 (93%)	
on	antipsychotic	polytherapy	did	not	have	an	adequate	trial	of	
monotherapy	(4-9	weeks	of	optimal	antipsychotic	monotherapy	
dose).27	Even	if	we	presumed	that	all	patients	on	antipsychotic	
polytherapy	were	truly	treatment	resistant,	Schumacher	et	al.	
found	that	97.6%	of	patients	did	not	receive	a	trial	of	clozapine,	
the	only	antipsychotic	proven	effective	 for	 treatment-resistant	
schizophrenia.	
High	 prevalence	 and	 lack	 of	 evidence	 about	 safety	 and	
efficacy	 have	 produced	 concerns	 about	 antipsychotic	 poly-
therapy.29,30	 Heeding	 these	 concerns,	 the	 Joint	 Commission	
in	October	2008	released	 the	 first	 set	of	hospital-based	 inpa-
tient	psychiatric	 services	 (HBIPS)	core	measures,	 including	2	
measures	 of	 antipsychotic	 polytherapy	 at	 discharge	 (Figure	
1).30 Patients	 discharged	 without	 antipsychotic	 medications	
represent	 a	 different	 population	 than	 those	 discharged	 with	
antipsychotic	 medications	 and	 are	 not	 included	 in	 the	 anti-
psychotic	polytherapy	core	measure.
In	anticipation	of	the	release	of	the	Joint	Commission’s	anti-
psychotic	polytherapy	core	measure,	the	study	authors	designed	
a	 quality	 improvement	project	 to	 address	 antipsychotic	 poly-
therapy.	 In	alignment	with	 the	 Joint	Commission’s	core	mea-
sure,	 the	 study’s	 primary	 outcome	 was	 use	 of	 antipsychotic	
polytherapy	 at	 discharge.	 Since	 the	 project	 began	 during	
development	 of	 the	 HBIPS	 core	 measure,	 initial	 data	 collec-
tion	was	based	on	early	drafts	of	 the	measure,	which	did	not	
include	a	measure	of	appropriate	justification	of	antipsychotic	
polytherapy.	 Therefore,	 data	 on	 justification	 of	 antipsychotic	
polytherapy	 were	 not	 collected	 during	 the	 earlier	 portion	 of	
our	intervention.	Once	the	core	measure	criteria	expanded	to	
include	appropriate	 justification	of	antipsychotic	polytherapy,	
we	began	to	collect	these	data.	
A ntipsychotic	 monotherapy	 with	 first-	 and	 second-generation	 antipsychotics	 has	 demonstrated	 efficacy	in	the	treatment	of	schizophrenia	and	other	psychotic	
disorders.1,2	However,	20%-35%	of	patients	fail	to	respond	to	or	
have	incomplete	response	to	antipsychotic	monotherapy.1,2	For	
such	 treatment-resistant	 patients,	 clozapine	 is	 the	 only	 treat-
ment	proven	effective.1-3	However,	clozapine	has	some	particu-
larly	dangerous	side	effects	and	requires	regular	monitoring	of	
white	blood	cell	 count,	 limiting	 its	use.	As	 a	 consequence	of	
this	problem,	clinicians	and	patients	struggle	to	find	an	effec-
tive	medication	 regimen.	 One	 particularly	 prevalent	medica-
tion	regimen	is	concomitant	prescription	of	2	or	more	standing	
antipsychotics	(antipsychotic	polytherapy).
Antipsychotic	polytherapy	has	not	been	consistently	proven	
effective	 or	 safe	 for	 patients	 with	 no	 or	 partial	 response	 to	
antipsychotic	monotherapy.4-6	 In	 the	majority	 of	 randomized	
controlled	 efficacy	 trials,	 antipsychotic	 polytherapy	 did	 not	
significantly	 differ	 from	 monotherapy	 on	 primary	 outcome	
measures.7-12	 Of	 the	 randomized	 controlled	 efficacy	 trials	
that	 found	 differences	 between	 groups	 on	 primary	 outcome	
measures,	2	studies	reported	antipsychotic	polytherapy	supe-
rior,11,12	and	1	reported	antipsychotic	monotherapy	more	effec-
tive.7	 Effects	 on	 secondary	 outcome	 measures	 were	 mixed,	
but	benefits	gained	with	polytherapy	were	often,	although	not	
always,	small.	Results	of	analyses	of	side	effects	with	polyther-
apy	are	mixed.7,9,11-15	Adherence	is	decreased	with	antipsychotic	
polytherapy,16	 and	 the	 additional	medication	 costs	 associated	
with	antipsychotic	polytherapy	do	not	 appear	 to	be	offset	by	
cost	savings	in	other	areas	of	treatment.17
Despite	these	mixed	data,	the	use	of	antipsychotic	polyther-
apy	is	common.18-20	Within	the	California	Medicaid	population	
in	2004,	an	estimated	13.7%	of	outpatients	with	 schizophre-
nia	 who	 were	 treated	 with	 antipsychotics	 received	 multiple	
second-generation	antipsychotics.18	Rates	are	even	higher	dur-
ing	psychiatric	inpatient	stays,	with	antipsychotic	polytherapy	
•	This	quality	improvement	program	can	serve	as	a	potential	model	
for	other	inpatient	facilities	trying	to	meet	the	Joint	Commission’s	
antipsychotic	polytherapy	HBIPS	core	measure.
•	At	baseline,	5.9%	of	patients	discharged	from	an	acute	inpatient	
psychiatric	stay	on	antipsychotic	medication	received	discharge	
prescriptions	for	3	or	more	antipsychotics.	After	the	provision	of	
education	to	psychiatrists	and	nurses,	that	rate	declined	to	2.5%.	
The	rate	further	declined	to	0.0%	following	the	delivery	of	feed-
back	from	11	monthly	audits	to	psychiatrists.	
•	Of	 389	 patients	 discharged	 on	 antipsychotics	 at	 baseline,	 132	
(33.9%)	were	prescribed	2	or	more	antipsychotics.	After	comple-
tion	 of	 the	 educational	 and	 audit	 feedback	 components	 of	 the	
program,	12.2%	(18	of	147	patients)	were	prescribed	2	or	more	
antipsychotics	at	discharge	(P <	0.001).	
What this study adds
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of	 antipsychotic	medications	prior	 to	 initiation	of	 the	quality	
improvement	program.
Educational Component
Reports	of	educational	efforts	to	improve	physician	adherence	
with	evidence-based	medicine	within	and	outside	of	psychia-
try	 have	 been	 mixed.31-34	 However,	 an	 educational	 program	
was	considered	by	the	study	authors	to	be	crucial	to	this	qual-
ity	 improvement	 program	 for	 several	 reasons,	 including	 the	
need	to	(a)	open	a	dialogue	regarding	goals	and	concerns	with	
the	 quality	 improvement	 program,	 (b)	 address	 the	 evidence	
base	supporting	the	quality	improvement	program,	(c)	obtain	
clinician	 “buy-in”	 for	 the	 program,	 and	 (d)	 allow	nurses	 and	
psychiatrists	 access	 to	 the	 same	 information	 regarding	 the	
purpose	 and	 methods	 of	 the	 quality	 improvement	 program.	
A	pharmacist	who	 is	board	certified	 in	psychiatric	pharmacy	
practice	worked	as	part	of	the	interdisciplinary	team	to	develop	
and	deliver	the	education.
Educational	 modules	 were	 developed	 using	 a	 discipline-
specific	approach.	Specific	learning	objectives	are	presented	in	
Table	1.	The	primary	educational	goal	was	to	ensure	realistic	
expectations	 of	what	 an	 antipsychotic	 could	 do	 and	 in	what	
time	 frame.	 The	 secondary	 educational	 goal	 was	 to	 initiate	
discussion	of	the	risks	of	antipsychotic	medications,	especially	
with	antipsychotic	polytherapy.	Discussions	centered	on	risks	
and	 benefits	 of	 antipsychotic	 monotherapy	 and	 polytherapy,	
relative	 risks	 and	 benefits	 of	 first-	 and	 second-generation	 
■■  Methods
All	data	were	gathered	as	part	of	a	quality	improvement	project.	
As	such,	our	local	institutional	review	board	deemed	publica-
tion	of	 research	using	de-indentified	patient	 and	psychiatrist	
data	 exempt	 from	 institutional	 review	 board	 approval.	 To	
ensure	confidentiality	during	the	project,	all	data	analyses	were	
conducted	 and	 reported	 for	 internal	 use	 with	 de-identified	
patient	data.
Setting
At	 the	 time	 of	 the	 quality	 improvement	 project,	 Cambridge	
Health	Alliance	(CHA),	a	regional	academic	health	care	system,	
consisted	 of	 3	 inpatient	 hospitals,	 more	 than	 20	 outpatient	
clinics,	 a	Medicaid	 health	maintenance	 organization	 (HMO),	
and	the	Cambridge	Public	Health	Department.	As	a	safety	net	
hospital	 system,	CHA	serves	a	 racially	and	ethnically	diverse	
population.	 Approximately	 50%	 of	 CHA	 patients	 are	 unin-
sured	 or	 enrolled	 in	 Medicaid	 or	 Commonwealth	 Care,	 the	
state	health	insurance	program.
During	 implementation	 of	 the	 quality	 improvement	 pro-
gram,	 CHA	 had	 4	 acute	 inpatient	 adult	 psychiatric	 units	
housed	 within	 2	 hospitals	 (2	 units	 at	 each	 hospital).	 Each	
adult	 inpatient	 psychiatric	 unit	 cares	 for	 approximately	 40	
patients	daily.	One	hospital	 follows	an	academic	model,	with	
residents,	 students,	 and	 interns	 involved	 in	patient	 care.	The	
other	 hospital	 follows	 a	 community	 model	 without	 trainee	
involvement.	There	were	no	prescribing	guidelines	for	the	use	
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FIGURE 1 The Joint Commission’s Hospital-Based Inpatient Psychiatric 
Service Core Measures on Antipsychotic Polypharmacya
Patients Discharged on Multiple Antipsychotic Medications
Denominator Statement: Psychiatric inpatient discharges 
Included Populations: 
•	 Patients	with	ICD-9-CM Principal or Other Diagnosis Codes for Mental Disorders as defined in Appendix A, Table 10.1 discharged on 
one or more routinely scheduled antipsychotic medications (refer to Appendix B, Table 10.0- Antipsychotic Medications) 
Excluded Populations: 
•	 Patients	who	expired	
•	 Patients	with	an	unplanned	departure	resulting	in	discharge	due	to	elopement	
•	 Patients	with	an	unplanned	departure	resulting	in	discharge	due	to	failing	to	return	from	leave	
Patients Discharged on Multiple Antipsychotic Medications with Appropriate Justification
Denominator Statement:	Psychiatric	inpatients	discharged	on	two	or	more	routinely	scheduled	antipsychotic	medications	
Included Populations: Not applicable 
Excluded Populations: 
•	 Patients	who	expired	
•	 Patients	with	an	unplanned	departure	resulting	in	discharge	due	to	elopement	
•	 Patients	with	an	unplanned	departure	resulting	in	discharge	due	to	failing	to	return	from	leave	
•	 Patients	with	a	length	of	stay	≤	3	days	
aThe Joint Commission. Specification Manual for National Quality Measures-Hospital-Based Inpatient Psychiatric Services Test Set.30
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
Non-commercial academic use only.
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antipsychotics,	 and	 use	 of	 antipsychotics	 for	 acute	 agitation	
versus	primary	psychosis.
All	11	inpatient	psychiatrists	met	as	a	group	4	times	during	
the	 9-month	 intervention	 period.	 The	 initial	 meetings	 were	
in	November	and	December	2006.	The	remaining	2	seminars	
were	conducted	quarterly	during	the	first	and	second	quarters	
of	2007.	The	meeting	site	was	varied	in	order	to	decrease	travel	
burden	 on	 any	 one	 group	 of	 psychiatrists.	 Core	 information	
was	 presented	 during	 lunch	 by	 the	 psychiatric	 pharmacist,	
chief	 of	 adult	psychiatry,	 and	 local	psychiatry	directors	 from	
each	 hospital.	 An	 interactive	 seminar	 format	 was	 used	 to	
present	 information	 and	 allow	 psychiatrists	 to	 provide	 input	
and	 express	 their	 concerns	 about	 antipsychotic	 polytherapy	
in	 the	 clinical	 setting.	 To	 engage	 psychiatrists	 in	 discussion,	
the	seminars	included	discussions	of	recent	patients	who	were	
particularly	complex	and	challenging.
Nursing	 staff	 were	 included	 for	 2	 reasons:	 (a)	 to	 prepare	
nursing	staff	for	possible	changes	in	prescribing	practices,	and	
(b)	 psychiatrists’	 prescribing	 can	 be	 influenced	 by	 nursing	
input,	specifically	 fears	about	violence	on	the	unit.	Given	the	
goal	of	preparing	nursing	staff	for	possible	prescribing	changes,	
similar	 educational	 content	was	provided	 to	 nurses	 and	psy-
chiatrists.	 Education	 for	 nursing	 staff	 was	 conducted	 during	
2007	Q1	through	a	series	of	lectures	delivered	by	the	psychiat-
ric	pharmacist	during	mandatory	nursing	“best	practice”	days.	
The	format	was	a	45-minute	lecture	with	a	15-minute	question	
and	answer	period.	A	 single	 lecture	was	delivered	7	 times	 to	
allow	 maximal	 nursing	 participation.	 Supplemental	 written	
materials	were	provided.	The	10%	of	psychiatric	nurses	unable	
to	 attend	 the	 lecture	 due	 to	 vacation	 or	 sick	 time	 received	 a	
printed	 copy	 of	 the	 lecture	 and	 contact	 information	 for	 the	
psychiatric	pharmacist.
Audit Feedback
Because	 of	 the	 extensive	 literature	 on	 audit	 feedback	 as	 a	
method	of	quality	improvement,31	the	educational	component	
was	combined	with	prescribing	feedback	to	improve	the	like-
lihood	 of	 success.	 Psychiatrists	 were	 provided	with	monthly	
“dashboard”	 (visual	 presentation	 of	 prescribing	 data)	 reports	
of	 their	 antipsychotic	 prescribing	 from	 August	 2007	 to	 June	
2008	 (Figure	 2).	 They	were	 also	 provided	with	 de-identified	
peer	 data	 for	 comparison.	 Data	 presented	 in	 the	 monthly	
dashboard	 included	 the	 number	 of	 patients	 treated,	 number	
of	 patients	 treated	 with	 antipsychotics,	 number	 of	 patients	
treated	with	monotherapy	 or	 polytherapy,	 patient	 diagnoses,	
and	 specific	 antipsychotic	 combinations	 used.	 Psychiatrists	
met	 individually	with	 the	chief	of	 service	quarterly	 to	review	
their	 antipsychotic	 prescribing	 dashboard,	 discuss	 concerns,	
and	 offer	 suggestions	 for	 improvements	 to	 the	 antipsychotic	
polytherapy	project.
Outcome Measures
In	 alignment	with	 the	 Joint	Commission	HBIPS-5	 core	mea-
sure,	the	primary	outcome	measure	was	the	number	of	patients	
discharged	 on	 2	 or	more	 standing	 antipsychotic	medications	
divided	by	the	number	of	patients	discharged	on	at	least	1	anti-
psychotic.30	Given	the	potential	for	increased	risks	and	paucity	
of	 data	 on	use	 of	 3	 or	more	 antipsychotics,	we	 believed	 this	
practice	 could	 never	 be	 justifiable.	 Therefore,	 the	 secondary	
outcome	measure	was	prescription	of	3	or	more	standing	anti-
psychotics	 at	 discharge.	 Information	 on	 patients	 discharged	
on	 no	 antipsychotic	was	 not	 reviewed	 because	 such	 patients	
represent	a	different	population	with	disorders	not	responsive	
to	antipsychotic	treatment.
Sample and Data Collection Process
All	 patients	 on	 regularly	 scheduled	 antipsychotic	medication	
for	any	indication	at	time	of	discharge	from	the	4	acute	adult	
inpatient	 units	 were	 included.	 Baseline	 data	 were	 collected	
prior	 to	 any	 discussion	 of	 antipsychotic	 polytherapy	 usage	
(August	 through	 October	 2006).	 Data	 following	 the	 educa-
tional	component	and	the	monthly	audit	component	were	col-
lected	 in	 July	 2007	 and	 June	2008,	 respectively.	Appropriate	
justification	data	were	collected	from	November	2007	until	the	
conclusion	 of	 the	 program	 in	 June	 2008.	Collection	 of	 these	
data	 coincided	 with	 inclusion	 of	 appropriate	 justification	 of	
antipsychotic	polytherapy	criteria	into	drafts	of	the	HBIPS	core	
measure.
Data	 were	 collected	 from	 the	 Meditech	 Health	 Care	
Information	 System,	 the	 electronic	 database	 used	 in	 CHA’s	
hospital	 system.	 Data	 collected	 included	 number	 of	 patients	
treated,	standing	antipsychotic	medications	at	the	time	of	dis-
charge,	and	diagnoses.	All	cases	of	antipsychotic	polytherapy	
were	 confirmed	 by	 a	 chart	 review	 conducted	 by	 the	 chief	
of	 adult	 psychiatry	 or	 chief	 of	 psychiatric	 quality	 improve-
ment.	Justification	of	antipsychotic	polytherapy	was	confirmed	
through	chart	review	by	the	chief	of	adult	psychiatry.
Data Analysis
A	 comparison	 of	 the	 use	 of	 antipsychotic	 polytherapy	 in	 the	
2	hospital	 settings	prior	 to	 education	was	performed	using	 a	
Pearson’s	 chi-square	 test	 of	 independence.	 As	 there	 were	 no	
significant	 differences	 between	 usage	 in	 these	 settings,	 data	
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TABLE 1 Educational Learning Objectives
•	 Describe	medical	risks	of	antipsychotic	medications
•	 Identify	specific	versus	nonspecific	effects	of	antipsychotic	
medications	(e.g.,	sedation	vs.	psychosis)
•	 Compare	and	contrast	effectiveness	and	safety	of	first-	and	second-
generation	antipsychotics
•	 Describe	data	regarding	the	safety	and	efficacy	of	antipsychotic	
polytherapy
Non-commercial academic use only.
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FIGURE 2 Sample Audit Feedback: Antipsychotic Prescribing “Dashboard”a
7/07 8/07 9/07 10/07 11/07 12/07 1/08 2/08 3/08 4/08 5/08 6/08
Prescriber X # Discharges 43 27 33 33 40 22 23 25 11 20 21 12
# Patients on  
antipsychotics
22 13 9 14 8 12 10 10 2 7 6 8
% Patients on  
antipsychotics
51 48 27 42 20 55 43 40 18 35 29 67
Patient Category 7/07 8/07 9/07 10/07 11/07 12/07 1/08 2/08 3/08 4/08 5/08 6/08
Overall  
discharge  
medication
Patients	with	1	
antipsychotic
22 13 7 11 8 11 10 10 2 7 6 8
Patients	with	2	
antipsychotics
2 3 1
Patients	with	3	
antipsychotics
Patients	with	4-5	
antipsychotics
Total 22 13 9 14 8 12 10 10 2 7 6 8
Drug ARIP CLOZ CPZ HPD HPD-D OZPA PER QTP RPR RPR-C ZIP FLU FLU-D
Patients  
discharged  
on 1 or 2  
antipsychotics
ARIP 1
CLOZ
CPZ 1
HPD
HPD-D
OZPA
PER
QTP 1
RPR 2
RPR-C
ZIP
FLU
FLU-D
Rationale No Yes 
Failed 
Mono
Yes 
Cross 
Taper
Yes 
Cross 
Taper
Patient Category Adjust Anx BPD MDD
Other Mood  
w/Psychosis Psychosis SA Eat Cog Total % Notes
Patients	with	1	 
antipsychotic
1 1 2 2 1 88% Percentages by 
diagnosis sum to 
more than 100% 
because patients 
can	have	more	
than 1 diagnosis.
Patients	with	2	 
antipsychotics
1 12%
Patients	with	3	 
antipsychotics
Patients	with	4-5	 
antipsychotics
Total % 13% 13% 25% 38% 13%
aNumbers shown in the “dashboard” are hypothetical and presented for purposes of illustration only.
Adjust = adjustment disorder; anx = anxiety disorder; ARIP = aripiprazole; BPD = bipolar disorder; CLOZ = clozapine; cog = cognitive disorder; CPZ = chlorpromazine; 
eat = eating disorder; FLU (D) = fluphenazine (decanoate); HPD-D = haloperidol (decanoate); MDD = major depressive disorder; Mono = monotherapy; OZPA = olanzapine; 
PER = perphenazine; QTP = quetiapine; RPR (C) = risperidone (consta); SA = substance abuse; ZIP = ziprasidone. 
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2).	Patient	 case	mix	 and	average	 length	of	 stay	did	not	differ	
between	 baseline	 and	 active	 intervention	 time	 periods	 (data	
not	shown).	
The	 frequency	of	 antipsychotic	polytherapy	decreased	 sig-
nificantly	after	the	educational	and	audit	feedback	components	
of	the	intervention	(Pearson	chi-square	=	28.81,	df	=	2,	P < 0.001; 
Figure	3).	In	July	2007,	after	the	educational	modules	had	been	
delivered,	 of	 202	 patients	 prescribed	 antipsychotics	 at	 dis-
charge,	44	(21.8%)	were	prescribed	2	or	more	antipsychotics.	
This	 rate	 represented	 an	 absolute	 reduction	 of	 12.1%	 com-
pared	with	baseline	 (Fisher’s	Exact	 test,	P =	0.002).	Following	
the	 audit	 intervention,	 there	 was	 a	 further	 reduction	 to	 an	
antipsychotic	 polytherapy	 rate	 of	 12.2%	 (18	 of	 147	patients),	
representing	 an	 absolute	 reduction	 of	 9.6%	 (Fisher’s	 Exact	
test,	P =	0.023).	The	Cochran-Armitage	test	for	trend	showed	a	
significant	(Pearson	chi-square	=	28.69,	df	=	1,	P	<	0.001)	linear	
decrease	in	the	proportion	of	patients	who	were	treated	with	2	
or	more	antipsychotic	drugs	over	the	3	time	periods	(i.e.,	using	
the	progressive	education	to	audit	strategy).
In	July	2007,	5	patients	(2.5%)	had	3	or	more	antipsychotics	
prescribed	 at	 discharge;	 that	 number	 declined	 to	 0	 in	 June	
2008.	 Combinations	 involving	 clozapine	 accounted	 for	 less	
than	 1%	 of	 antipsychotic	 polytherapy	 at	 all	 time	 points.	
When	 antipsychotic	 usage	was	 classified	 as	 the	 frequency	 of	
patients	 receiving	 1,	 2,	 or	 3	 or	 more	 antipsychotic	 medica-
tions,	 the	 incremental	 intervention	 (i.e.,	 3	 time	 periods)	was	
associated	with	decreased	combination	use	(Goodman-Kruskal	
gamma	=	0.39,	P <	0.001).	
Justification	 of	 antipsychotic	 polytherapy	 data	 were	 col-
lected	 from	 November	 2007	 until	 conclusion	 of	 the	 quality	
improvement	project.	Rates	of	appropriate	justification	ranged	
from	21%	to	100%.
■■  Discussion
Our	 findings	 of	 decreased	 antipsychotic	 polytherapy	 during	
a	 quality	 improvement	 program	 are	 consistent	with	 those	 of	
other	reports	in	the	literature.	Similar	to	our	report,	successful	
interventions	 typically	 include	 multifaceted	 approaches.32-34	
The	present	study	is	the	first,	to	our	knowledge,	to	find	an	asso-
ciation	 between	 the	 combination	 of	 discipline-specific	 group	
education	for	nursing	and	psychiatry	staff	with	audit	feedback	
and	reduced	rates	of	antipsychotic	polytherapy.
Other	 reports	 address	 interventions	 to	 decrease	 anti-
psychotic	 polytherapy	 with	 different	 quality	 improvement	
programs.	Mason	et	al.	(1978)	first	reported	more	than	30	years	
ago	 on	 attempts	 to	 reduce	 antipsychotic	 polytherapy	 in	 state	
psychiatric	hospitals.35	The	authors	reported	that	peer	review,	
small	 group	 educational	 sessions,	 audit	 feedback,	 and	 writ-
ten	educational	materials	on	basic	principles	of	antipsychotic	
prescribing	led	to	a	rate	of	antipsychotic	polytherapy	of	152	of	
802	(19.0%)	at	follow-up	compared	with	357	of	1,190	(30.0%)	
at	baseline.
were	 combined	 across	 settings.	 Fisher’s	Exact	 tests	were	per-
formed	on	the	primary	outcome	measure,	receipt	of	2	or	more	
antipsychotics	at	discharge.	These	tests	compared	(a)	July	2007	
(the	month	following	completion	of	the	education)	with	August	
through	October	2006	(the	baseline	period)	and	(b)	June	2008	
(the	month	following	the	completion	of	the	monthly	provider-
specific	 feedback)	 with	 July	 2007.	 A	 Pearson	 chi-square	 test	
of	 independence	 and	 a	 Cochran-Armitage	 test	 assessed	 the	
significance	 and	 trend	 of	 the	 relationship	 between	 the	 inter-
vention	and	antipsychotic	polytherapy,	using	a	2	X	3	table	of	
the	 antipsychotic	 polytherapy	measure	 (i.e.,	 1	 vs.	 2	 or	more	
antipsychotics	at	discharge	over	the	3	time	periods—baseline,	
then	education	alone,	then	education	plus	monthly	feedback).	
The	strength	of	the	association	between	the	prescription	of	1,	
2,	or	3	 antipsychotics	 and	 increasing	 intervention	 (i.e.,	 the	3	
time	periods)	was	assessed	using	a	Goodman-Kruskal	gamma	
test.	 Because	 no	 cells	 had	 less	 than	 5	 expected	 cases,	 conti-
nuity	 correction	was	not	 required	 for	 the	Pearson	 chi-square	
tests.	The	a	priori	P	value	for	statistical	significance	was	0.05.	
All	statistical	analyses	were	performed	with	Systat	12.0	(Systat	
Software	Inc.,	Chicago,	IL).
■■  Results
There	were	389	patients	prescribed	at	least	1	antipsychotic	at	
discharge	during	the	baseline	period.	Bipolar	disorder	was	the	
most	 common	 diagnosis	 (37.0%)	 followed	 by	 schizophrenia/
schizoaffective	 disorder/schizophreniform	 disorder	 (32.9%),	
major	depression	(28.0%),	other	mood	disorder	with	psychosis	
(2.1%),	 and	 other	 (3.1%).	 Patients	 could	 be	 diagnosed	 with	
more	than	1	primary	psychiatric	disorder;	hence,	 the	total	of	
reported	diagnoses	exceeds	100%.	During	the	baseline	period,	
109	 (28.0%)	 of	 patients	 were	 treated	 with	 2	 antipsychotics,	
and	23	(5.9%)	were	treated	with	3	antipsychotics	at	discharge,	
for	 an	 overall	 antipsychotic	 polytherapy	 rate	 of	 33.9%	 (Table	
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TABLE 2 Antipsychotic Use at Psychiatric 
Hospital Discharge
Date
Patients on 1 
Antipsychotic
Patients on 2 or More 
Antipsychotics P Valuea
August	through	
October	2006	 
(baseline)b 
	 257	 (66.1%) 	 132	 (33.9%)c
July	2007b 	 158	 (78.2%) 	 44	 (21.8%)c 0.002
June	2008b 	 129	 (87.8%) 	 18	 (12.2%)c 0.023
aFisher’s Exact tests comparing July 2007 with August through October 2006 (sec-
ond row) and June 2008 with July 2007 (third row).
bAugust through October 2006 is baseline prior to education; July 2007 is the 
month following education provided to psychiatrists and nurses from November 
2006 through June 2007; and June 2008 is after monthly audit and feedback pro-
cess performed from August 2007 through June 2008. 
cCounts (%) of patients with 3 antipsychotic medications in baseline, July 2007, 
and June 2008, were 23 (5.9%), 5 (2.5%), and 0, respectively. P value for compari-
son of baseline and June 2008 was < 0.001 by Fisher’s Exact test.
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the	modules	during	normal	working	 shifts.	This	 feature	may	
have	 improved	 the	 palatability	 of	 educational	 programs	 to	
psychiatric	physicians	 and	nursing	 staff.	This	difference	may	
partially	account	for	the	present	study’s	finding	of	an	absolute	
22%	decrease	in	rates	of	antipsychotic	polytherapy.
The	 present	 study’s	 authors	 noted	 a	 decrease	 in	 the	most	
egregious	 form	of	 antipsychotic	polytherapy	 (3	or	more	 anti-
psychotics)	after	the	introduction	of	educational	programming	
only.	Therefore,	group	education	may	be	useful	 in	decreasing	
the	most	 egregious	 form	 of	 antipsychotic	 polytherapy.	 Study	
results,	 which	 represent	 academic	 and	 community	 hospitals,	
demonstrate	that	focused	educational	group	sessions	have	the	
potential	for	broad	application.
Limitations
First,	the	health	care	system	in	which	the	present	study	was	con-
ducted	is	a	public	health	safety	net	hospital	system.	Additionally,	
33%	 of	 sample	 patients	 were	 diagnosed	 with	 schizophrenia,	
schizoaffective	 disorder,	 or	 schizophreniform	 disorder,	 and	
55%	 were	 diagnosed	 with	 bipolar	 disorder	 or	 major	 depres-
sion.	As	such,	our	population	may	not	necessarily	reflect	other	
patient	populations,	 including	 those	 in	other	 facilities	or	with	
a	different	diagnostic	profile.	Second,	this	study	reflects	only	a	
limited	number	of	staff	psychiatrists	(n	=	11).	It	is	possible	that	
other	psychiatrists	may	be	more	resistant	to	prescribing	change.	
However,	 the	 study	 investigators	noted	 improvements	 in	 anti-
psychotic	prescribing	patterns	in	all	11	psychiatrists.
In	another	study,	Chong	et	al.	(2006)	developed	and	imple-
mented	 an	 evidence-based	 treatment	 algorithm	 for	 patients	
accepted	 into	 an	 early	 psychosis	 intervention	 program.36 
Introduction	 of	 the	 algorithm	was	 associated	with	 decreased	
antipsychotic	 polytherapy.	 However,	 the	 algorithm	 was	 for	
“first	break”	psychosis	 and	may	not	be	applicable	 to	patients	
who	have	been	ill	for	many	years.	
In	the	previous	research	most	similar	to	the	present	study,	
Thompson	 et	 al.	 (2008)	 reported	 a	 decrease	 in	 antipsychotic	
polytherapy	in	a	randomized	controlled	trial	involving	19	psy-
chiatric	units	that	 included	a	3-part	 intervention	of	academic	
detailing,	 chart-based	 reminders,	 and	 an	 educational	 work-
book	documenting	alternatives	to	polytherapy,	including	cog-
nitive	 behavioral	 techniques.32	 Cognitive	 challenges	 to	 poly-
pharmacy	prescribing	were	identified	from	the	rationales	used	
by	clinicians	to	justify	polypharmacy,	and	alternatives	to	poly-
pharmacy	were	reviewed	in	workbooks	provided	to	nurses	and	
physicians.	Initial	rates	of	polytherapy	were	71	of	204	(34.8%)	
and	130	of	270	(48.1%)	patients	on	the	control	and	intervention	
units,	respectively.	Upon	completion	of	the	interventions,	poly-
therapy	was	prescribed	 in	92	of	220	(41.8%)	and	104	of	260	
(40.0%)	patients	on	the	control	and	intervention	units,	respec-
tively.	 However,	 given	 the	 modest	 gains	 and	 labor-intensive	
efforts,	 the	 authors	 recommended	 caution	 when	 interpreting	
their	results.	In	contrast,	the	process	described	in	the	present	
study	was	less	labor	intensive.	We	did	not	rely	on	staff	commit-
ment	of	personal	time	for	the	educational	program,	providing	
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FIGURE 3 Antipsychotic Polytherapy Rates
aStarting November 2006.
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